Price orphan drugs can be reduced drastically
Skyrocketing healthcare costs need to be held in check
PW Magazine 39, jaar 2012
-
28-09-2012
|
door J.R.B.J. Brouwers
Better diagnostic testing allows tailored therapy for an increasing number of diseases. This has led to a growing number of conditions classified as ‘orphan diseases’. A welcome source of income for the pharmaceutical industry, but a growing expense for society. It’s time for a change of course.
Wilt u verder lezen?
Log in om verder te lezen.
Ik ben mijn wachtwoord vergeten
Alleen abonnees van het Pharmaceutisch Weekblad hebben volledige toegang tot pw.nl. Ga voor meer informatie: abonnement PW aanvragen.